// App-Quantinova.ai

AEP628 : Safety and IGF-1 levels with once daily oral sst2 agonist paltusotine (CRN00808) in acromegaly patients previously treated with peptide long-acting somatostatin receptor ligands: Initial data from the open label ACROBAT Edge phase 2 study

Researchers

Presenter

  • Miklos Toth

Principal Investigators

  • Murray Gordon

  • Mirjana Doknic

  • Emese Mezosi

  • Harpal Randeva

  • Tonya Marmon

  • Kim Fowler

  • Rosa Luo

  • Michael Monahan

  • Ajay Madan

  • Chris Ferrara-Cook

  • R. Scott Struthers

  • Alan Krasner

Medical Centers

  • Semmelweis University, Budapest, Hungary

  • Nephrology, Allegheny General Hospital, Pittsburgh, United States

  • Clinical Center of Serbia, Belgrade, Serbia

  • Univ Pécs Medical School, Pécs, Hungary

  • University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

  • Crinetics Pharmaceuticals Inc, San Diego, United States

Locations

  • Hungary

  • United States

  • Serbia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acromegaly

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type F

  • Insulin-like growth factor 1

Drug/Treatment

  • Pasireotide

  • Somatostatin

  • Pegvisomant

  • Dopamine hydrochloride

  • Mecasermin

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved